{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:32Z","timestamp":1793496092280,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"DOI":"10.1007\/s00702-026-03185-1","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:53:00Z","timestamp":1780411980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Beyond \u201cAdvanced\u201d: proposing Fluctuation-Dominant Parkinson\u2019s disease as a functional alternative to enable timely device-aided therapy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2138-1108","authenticated-orcid":false,"given":"Shivam Om","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"3","key":"3185_CR1","first-page":"513","volume":"37","author":"A Antonini","year":"2021","unstructured":"Antonini A, Stoessl AJ, Kleinman LS et al (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-consensus study. Curr Med Res Opin 37(3):513\u2013527","journal-title":"Curr Med Res Opin"},{"key":"3185_CR2","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","volume":"130","author":"M Auffret","year":"2023","unstructured":"Auffret M, Weiss D, Stocchi F et al (2023) Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty. J Neural Transm 130:1411\u20131432","journal-title":"J Neural Transm"},{"key":"3185_CR3","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00702-025-02989-x","volume":"132","author":"M Auffret","year":"2025","unstructured":"Auffret M, Borovecki F, Heim B et al (2025) Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson\u2019s disease. J Neural Transm 132:1727\u20131750","journal-title":"J Neural Transm"},{"issue":"4","key":"3185_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/mds.25844","volume":"29","author":"D Berg","year":"2014","unstructured":"Berg D, Postuma RB, Bloem B et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson\u2019s disease. Mov Disord 29(4):454\u2013462","journal-title":"Mov Disord"},{"issue":"4","key":"3185_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJS, Tsutsui H et al (2021) Universal definition and classification of heart failure. J Card Fail 27(4):387\u2013413","journal-title":"J Card Fail"},{"key":"3185_CR6","doi-asserted-by":"crossref","unstructured":"Reddy P, Martinez-Martin P, Brown RG et al (2013) Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). Health Qual Life Outcomes. 12:11. doi: 10.1186\/1477-7525-12-11.","DOI":"10.1186\/1477-7525-12-11"},{"issue":"Suppl 1","key":"3185_CR7","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.parkreldis.2016.11.018","volume":"33","author":"KR Chaudhuri","year":"2016","unstructured":"Chaudhuri KR, Bhidayasiri R, van Laar T (2016) Unmet needs in Parkinson\u2019s disease: new horizons in a changing landscape. Parkinsonism Relat Disord 33(Suppl 1):S2\u2013S8","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"3185_CR8","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1111\/ene.15386","volume":"29","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J et al (2022) European Academy of Neurology\/Movement Disorder Society-European Section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Eur J Neurol Mov Disord 29(9):2580-2595","journal-title":"Eur J Neurol"},{"issue":"5","key":"3185_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","volume":"23","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Stocchi F, Pahwa R et al (2024) Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson\u2019s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol 23(5):465\u2013476","journal-title":"Lancet Neurol"},{"key":"3185_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung VSC, Lopiano L et al (2019) Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol 19:50","journal-title":"BMC Neurol"},{"issue":"5","key":"3185_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11606-017-4289-2","volume":"33","author":"AP Goddu","year":"2018","unstructured":"Goddu AP, O\u2019Conor KJ, Lanzkron S et al (2018) Do words matter? Stigmatizing language and the transmission of bias in the medical record. J Gen Intern Med 33(5):685\u2013691","journal-title":"J Gen Intern Med"},{"key":"3185_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf775","author":"H Habibi","year":"2026","unstructured":"Habibi H et al (2026) Heart failure: terminology matters. Eur Heart J16;47(3):285 https:\/\/doi.org\/10.1093\/eurheartj\/ehaf775","journal-title":"Eur Heart J"},{"issue":"5","key":"3185_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427\u2013442","journal-title":"Neurology"},{"issue":"8","key":"3185_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/1474515119874538","volume":"18","author":"SE Ivynian","year":"2019","unstructured":"Ivynian SE, Ferguson C, Davidson PM (2019) Time to re-think the terminology of heart failure? Eur J Cardiovasc Nurs 18(8):648\u2013650","journal-title":"Eur J Cardiovasc Nurs"},{"key":"3185_CR15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00702-023-02733-3","volume":"131","author":"WH Jost","year":"2024","unstructured":"Jost WH (2024) Advanced is advanced is advanced is advanced. J Neural Transm 131:1275\u20131276","journal-title":"J Neural Transm"},{"key":"3185_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4047392","author":"MR Luquin","year":"2017","unstructured":"Luquin MR, Kulisevsky J, Martinez-Martin P et al (2017) Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study).Parkinsons Dis 4047392. https:\/\/doi.org\/10.1155\/2017\/4047392","journal-title":"Parkinsons Dis"},{"key":"3185_CR17","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/mdc3.13913","volume":"10","author":"HR Moes","year":"2023","unstructured":"Moes HR, Ten Kate JM, Buskens E et al. (2023a) Patient referral for device-aided therapies in Parkinson\u2019s disease is suboptimal: a Dutch survey. Mov Disord Clin Pract 10:1821\u20131823","journal-title":"Mov Disord Clin Pract"},{"issue":"11","key":"3185_CR18","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00702-023-02656-z","volume":"130","author":"HR Moes","year":"2023","unstructured":"Moes HR, Henriksen T, S\u0142awek J et al (2023b) Tools and criteria to select patients with advanced Parkinson\u2019s disease for device-aided therapies: a narrative review. J Neural Transm 130(11):1359\u20131377","journal-title":"J Neural Transm"},{"key":"3185_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","volume":"403","author":"T Foltynie","year":"2024","unstructured":"Foltynie T, Bruno V, Fox Set al (2024) Medical, surgical, and physical treatments for Parkinson\u2019s disease. Lancet 403:305\u2013324","journal-title":"Lancet"},{"issue":"12","key":"3185_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099\u20131109","journal-title":"Lancet Neurol"},{"key":"3185_CR21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00702-017-1799-3","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova N, Martinez-Martin P, Katunina E, Chaudhuri KR et al (2017) Advanced Parkinson\u2019s or \u201ccomplex phase\u201d Parkinson\u2019s disease? Re-evaluation is needed. J Neural Transm 124:1529\u20131537","journal-title":"J Neural Transm"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03185-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03185-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03185-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:53:04Z","timestamp":1780411984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03185-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":21,"alternative-id":["3185"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03185-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}